epilepsy%20(pediatric)
EPILEPSY (PEDIATRIC)
Epileptic seizure is a transient occurrence of signs or symptoms that is due to abnormal excessive or synchronous neuronal activity in the brain.
Epilepsy is a disorder that is characterized by a persistent predisposition of the brain to generate epileptic seizures.
This condition may cause neurobiologic, cognitive, psychological and social disturbances.
It is recommended that all patients having a first seizure be referred to a specialist as soon as possible.

Epilepsy%20(pediatric) Treatment

Principles of Therapy

In most clinical settings, seizures are not treated unless ≥2 unprovoked seizures are demonstrated within a 6-month period

Patient Experiences a Single Seizure

  • Detailed history needs to be taken to rule out any previous absence, myoclonic, or partial seizures because patients with undiagnosed epilepsy may present with a single generalized tonic-clonic seizure

Decision to Treat Single Seizure

  • Whether or not to treat a single seizure will be based upon the estimates of risk recurrence which vary
    • Highest recurrence risk rates (up to 90%) are seen in patients who demonstrate epileptic discharges on EEG or have congenital neurological deficits
    • Lowest recurrence risk rates (13-40%) are in patients who experience acute symptomatic seizures (provoked) or those with a normal EEG and no identifiable cause for seizure
  • Treatment with anticonvulsants can reduce the risk of recurrence by half
    • Early treatment has not shown to alter the prognosis of epilepsy
  • Consultation with epilepsy specialist will be needed to decide whether or not to treat a single seizure

Single Generalized Tonic-Clonic Seizure

  • Patient could be given anticonvulsant therapy if:
    • History of previous myoclonic, absence or focal seizures
    • EEG shows unquestionable epileptic discharges
    • Structural abnormalities are present in brain imaging
    • Patient has congenital neurological deficit
    • Patient decides the risk of recurrence is not acceptable

Pharmacological Therapy

  • Treatment initiation using a single antiepileptic drug is recommended
  • Shifting to another monotherapy may be done if initial treatment is unsuccessful
  • If with continued treatment failure, may add a 2nd drug and gradually increase to maximum tolerated dose while simultaneously tapering dose of 1st drug
  • Combination therapy may be considered if removal of the initial or 2nd drug is still ineffective
    • Consider combination therapy if patient has substantial seizure control with 1st-line agent but still experiences seizures at maximum dose
    • If various combinations fail to confer seizure freedom, return to the combination with the best control of seizures and best tolerability
    • Drugs used in combination should be matched to patient’s seizure type
    • Maximum 3 drugs can be combined; better if only 2 are used
      • Combined antiepileptic drugs should have different mechanisms of action

Pharmacotherapy

Anticonvulsants (1st-Line Anticonvulsants)

Choice of anticonvulsant drugs will be based on their indications, adverse effects and interaction profiles

Carbamazepine

  • Used as 1st-line therapy for newly diagnosed focal seizures and 1st-line therapy option for patients with primary generalized tonic-clonic seizures unresponsive or with contraindications to Valproate therapy
  • Also used as 1st-line treatment for patients with benign epilepsy associated with centrotemporal spikes, Panayiotopoulos syndrome, or late-onset childhood occipital epilepsy (Gastaut type)
  • Also used as adjunctive treatment for focal seizures and benign epilepsy associated with centrotemporal spikes, Panayiotopoulos syndrome, or late-onset childhood occipital epilepsy (Gastaut type) 
  • Should be avoided in absence, myoclonic, tonic and atonic seizures, idiopathic generalized epilepsy, juvenile myoclonic epilepsy and Lennox-Gastaut syndrome
  • Classification: Dibenzazepine derivative

Ethosuximide

  • Used as first-line therapy to treat absence seizures
  • Also used in childhood or juvenile absence epilepsy in combination with Lamotrigine or Valproate if unresponsive to 2 1st-line antiepileptic drugs
    • Use of Valproate for girls with childbearing potential should be avoided
  • Classification: Succinimide compound

Lamotrigine

  • Used as 1st-line therapy for newly diagnosed focal seizures, primary generalized tonic-clonic and absence seizures, and benign epilepsy associated with centrotemporal spikes, Panayiotopoulos syndrome, or late-onset childhood occipital epilepsy (Gastaut type)
    • Treatment option for patients with absence seizures unresponsive to Ethosuximide or Valproate
  • May also be used as 1st-line treatment for idiopathic generalized onset epilepsy and juvenile myoclonic epilepsy if Valproate is ineffective or not tolerated
  • Also used as adjunctive treatment for focal seizures, generalized tonic or atonic seizure, Lennox-Gastaut syndrome, idiopathic generalized epilepsy, juvenile myoclonic epilepsy, and benign epilepsy associated with centrotemporal spikes, Panayiotopoulos syndrome, or late-onset childhood occipital epilepsy (Gastaut type) and as tertiary therapy for myoclonic seizures
  • Also used in childhood or juvenile absence epilepsy in combination with Ethosuximide or Valproate if unresponsive to 2 1st-line antiepileptic drugs
    • Use of Valproate for girls with childbearing potential should be avoid
  • Classification: Phenyltriazine compound

Levetiracetam

  • Used as 1st-line therapy option for newly diagnosed focal seizures, primary generalized myoclonic seizures, idiopathic generalized epilepsy, and juvenile myoclonic epilepsy
  • Also used as adjunctive treatment for focal seizures, primary generalized tonic-clonic seizures, myoclonic seizures, idiopathic generalized epilepsy, juvenile myoclonic epilepsy, and benign epilepsy associated with centrotemporal spikes, Panayiotopoulos syndrome, or late-onset childhood occipital epilepsy (Gastaut type) and tertiary therapy for absence seizures
  • Also recommended as 2nd-line therapy for patients with benign epilepsy associated with centrotemporal spikes, Panayiotopoulos syndrome, or late-onset childhood occipital epilepsy (Gastaut type) if treatment failure with Carbamazepine or Lamotrigine occurs
  • Classification: Analogue of Piracetam which is a nootropic

Oxcarbazepine

  • Used as alternative 1st-line monotherapy for newly diagnosed focal to bilateral tonic-clonic seizure, for primary generalized tonic-clonic seizures benign epilepsy associated with centrotemporal spikes, Panayiotopoulos syndrome, or late-onset childhood occipital epilepsy (Gastaut type)
    • At 2400 mg/day, was shown to be effective in monotherapy for refractory focal epilepsy
  • Recommended as adjunctive treatment for patients with focal seizures, benign epilepsy associated with centrotemporal spikes, Panayiotopoulos syndrome, or late-onset childhood occipital epilepsy (Gastaut type)
  • Similar efficacy to Carbamazepine
    • Additional benefits were seen when Oxcarbazepine was added to Carbamazepine therapy
  • Better tolerated than Carbamazepine, fewer drug interactions and less physician monitoring is required
  • Should be avoided in absence, tonic or atonic seizures, Lennox-Gastaut syndrome, idiopathic generalized epilepsy, juvenile myoclonic epilepsy and myoclonic seizures
  • Classification: 10-keto analogue of Carbamazepine

Topiramate

  • Used as first-line monotherapy in patients with generalized myoclonic seizures, in newly diagnosed patients with epilepsy, or conversion to monotherapy, or as adjunctive treatment for newly diagnosed focal seizure, generalized tonic-clonic seizures, myoclonic seizures, idiopathic generalized epilepsy, juvenile myoclonic epilepsy, Lennox-Gastaut syndrome and benign epilepsy associated with centrotemporal spikes, Panayiotopoulos syndrome, or late-onset childhood occipital epilepsy (Gastaut type)
    • Also used as tertiary treatment for patients with generalized absence and tonic or atonic seizures
    • In some countries, Topiramate is only approved as adjunctive treatment
  • May also be used as 1st-line treatment for idiopathic generalized epilepsy, myoclonic epilepsy of infancy, juvenile myoclonic epilepsy, and patients with Dravet syndrome
  • Classification: Sulfamate-substituted monosaccharide

Valproate (Divalproex, Sodium Valproate, Valproic Acid)

  • Used as 1st-line therapy to treat newly diagnosed focal seizures, generalized tonic-clonic seizures, absence seizures, myoclonic seizures, tonic or atonic seizures, all generalized seizures, and idiopathic generalized epilepsy
  • May also be used as 1st-line therapy for juvenile myoclonic epilepsy, Dravet syndrome, Lennox-Gastaut syndrome and benign epilepsy associated with centrotemporal spikes, Panayiotopoulos syndrome, or late-onset childhood occipital epilepsy (Gastaut type)
  • Also used as adjunctive treatment for focal seizures, generalized tonic-clonic seizures, myoclonic seizures, idiopathic generalized epilepsy, juvenile myoclonic epilepsy and benign epilepsy associated with centrotemporal spikes, Panayiotopoulos syndrome, or late-onset childhood occipital epilepsy (Gastaut type)
  • The use of Valproic acid in combination with Lamotrigine or Ethosuximide for childhood absence epilepsy maybe considered for patients unresponsive to 2 1st-line antiepileptic drugs
  • Use of Valproate for girls with childbearing potential should be avoided
  • Important adverse effect is weight gain
  • Classification: Carboxylic acid derivative

Anticonvulsants (Adjunctive/Tertiary Anticonvulsants)

  • Recommended for patients who have not benefited from treatment with 1st-line antiepileptic medications or for whom these drugs are not suitable (eg poor tolerance, contraindications to 1st-line drugs, etc)

Brivaracetam

  • Recently approved as monotherapy or adjunctive therapy for focal onset seizures in patients ≥4 years old as oral therapy and for patients ≥16 years old as both oral and intravenous therapy
  • Classification: 2-pyrrolidine derivative and Levetiracetam analog

Eslicarbazepine acetate

  • Used as tertiary treatment for refractory focal seizure and benign epilepsy associated with centrotemporal spikes, Panayiotopoulos syndrome, or late-onset childhood occipital epilepsy (Gastaut type) if adjunctive therapies are ineffective or not tolerated
  • Classification: Carboxamide derivative

Felbamate

  • Used as adjunctive treatment for seizure associated with Lennox-Gastaut syndrome if all antiepileptic medications have been deemed ineffective

Gabapentin

  • Used as adjunctive treatment for focal seizure and benign epilepsy associated with centrotemporal spikes, Panayiotopoulos syndrome, or late-onset childhood occipital epilepsy (Gastaut type)
  • Should be avoided in absence and myoclonic seizures, Lennox-Gastaut syndrome, idiopathic generalized epilepsy and juvenile myoclonic epilepsy
  • Classification: Gamma-aminobutyric acid (GABA) analogue

Lacosamide

  • Used as tertiary treatment for refractory focal onset seizure and benign epilepsy associated with centrotemporal spikes, Panayiotopoulos syndrome, or late-onset childhood occipital epilepsy (Gastaut type) if adjunctive therapies are ineffective or not tolerated

Perampanel

  • Used as adjunctive treatment for patients ≥12 years of age with generalized tonic-clonic seizures and as tertiary therapy for focal epilepsy
  • Classification: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor antagonist

Phenobarbital (Phenobarbitone)

  • Tertiary treatment option for patients with focal onset seizures, generalized tonic-clonic, tonic and atonic seizures, neonatal seizure, benign epilepsy associated with centrotemporal spikes, Panayiotopoulos syndrome, or late-onset childhood occipital epilepsy (Gastaut type), and status epilepticus
  • Consider as a last-line agent; may have adverse effect on patient’s cognition
  • Should be avoided in absence seizures
  • Classification: Barbiturate

Phenytoin

  • Tertiary treatment option for patients with focal onset seizures, generalized tonic-clonic seizures, benign epilepsy associated with centrotemporal spikes, Panayiotopoulos syndrome, or late-onset childhood occipital epilepsy (Gastaut type) and status epilepticus
    • Valproate and Carbamazepine may be preferred since they tend to have fewer adverse effects
  • Should be avoided in absence seizures, idiopathic generalized epilepsy and juvenile myoclonic epilepsy 
  • Classification: Hydantoin compound
  • Associated with gum hypertrophy

Pregabalin

  • Used as tertiary treatment for patients with refractory focal onset seizures and benign epilepsy associated with centrotemporal spikes, Panayiotopoulos syndrome, or late-onset childhood occipital epilepsy (Gastaut type)
  • Should be avoided in absence seizures, tonic or atonic seizures, idiopathic generalized epilepsy, Lennox-Gastaut syndrome and juvenile myoclonic epilepsy
  • Classification: GABA analogue

Primidone

  • Used as tertiary treatment for focal onset seizures, and generalized tonic-clonic seizures
  • Classification: Barbiturate, related to Phenobarbital and partially metabolized to Phenobarbital

Rufinamide

  • Used as tertiary treatment for generalized tonic or atonic seizures, and adjunctive therapy for Lennox-Gastaut syndrome in children ≥4 years old
  • Classification: Carboxamide derivative

Stiripentol

  • Used as adjunctive treatment for patients with Dravet syndrome
  • Classification: GABA analogue

Tiagabine

  • Used as tertiary therapy for refractory focal onset seizures and benign epilepsy associated with centrotemporal spikes, Panayiotopoulos syndrome, or late-onset childhood occipital epilepsy (Gastaut type)
  • Should be avoided in generalized tonic-clonic, absence and myoclonic seizures, idiopathic generalized epilepsy, juvenile myoclonic epilepsy and Lennox-Gastaut syndrome
  • Classification: Nipecotic acid derivative

Vigabatrin

  • Used as tertiary therapy for refractory focal seizure and benign epilepsy associated with centrotemporal spikes, Panayiotopoulos syndrome, or late-onset childhood occipital epilepsy (Gastaut type)
    • Should be reserved for patients not adequately controlled by other agents
  • 1st-line treatment for patients with infantile spasms that may or may not be due to tuberous sclerosis
  • Should be avoided in generalized tonic-clonic, absence and myoclonic seizures, idiopathic generalized epilepsy and juvenile myoclonic epilepsy
  • Associated with visual field impairment in adults but few data exist in pediatric patients
  • Classification: GABA analogue

Zonisamide

  • Used as tertiary treatment for refractory focal seizure, generalized absence, myoclonic seizures and benign epilepsy associated with centrotemporal spikes, Panayiotopoulos syndrome, or late-onset childhood occipital epilepsy (Gastaut type)
  • Also used as adjunctive treatment for juvenile myoclonic epilepsy, idiopathic generalized epilepsy and refractory focal epilepsy
  • Classification: Benzisoxazole derivative

Benzodiazepines

Use of benzodiazepines may be limited by development of tolerance and sedation; other antiepileptics are usually preferred

Clobazam

  • Recommended as adjunctive treatment for patients with focal seizures, generalized tonic-clonic seizures, benign epilepsy associated with centrotemporal spikes, Panayiotopoulos syndrome, or late-onset childhood occipital epilepsy (Gastaut type), and Lennox-Gastaut syndrome
  • Also used as tertiary treatment for patients with generalized absence, myoclonic seizures, idiopathic generalized epilepsy, juvenile myoclonic epilepsy, and Dravet syndrome
  • Actions: Long-acting benzodiazepine with similar actions to Diazepam

Clonazepam

  • Also used as tertiary treatment for focal to bilateral tonic-clonic seizure, generalized absence seizures, generalized myoclonic seizures, idiopathic generalized epilepsy and juvenile myoclonic epilepsy
  • Used as an alternative to other antiepileptics in status epilepticus
  • Actions: Long-acting benzodiazepine with similar actions to Diazepam

Diazepam

  • Used as an adjunctive treatment for all types of seizures and status epilepticus
  • Actions: Long-acting benzodiazepine which acts by enhancing GABA activity in the brain

Lorazepam

  • Used as 1st-line agent in the treatment of status epilepticus
    • Advantageous to Diazepam in status epilepticus because it has a longer duration of action
    • Disadvantage: Parenteral form requires refrigeration
  • Actions: Long-acting benzodiazepine with similar actions to Diazepam

Midazolam

  • Used to treat status epilepticus resistant to treatment by Diazepam, Lorazepam and Phenytoin
  • Actions: Short-acting benzodiazepine with similar actions to Diazepam

Nitrazepam

  • Used to treat epilepsy especially infantile spasm
  • Actions: Intermediate-acting benzodiazepine with similar actions to Diazepam

Others

Acetazolamide

  • Used as adjunctive treatment for refractory focal to bilateral tonic-clonic seizure, atypical absence, tonic, atonic and myoclonic seizures resistant to conventional treatment
  • Actions: Inhibits carbonic anhydrase in glial cells in central nervous system (CNS)

Paraldehyde

  • Used to treat status epilepticus resistant to conventional treatment
    • Use is limited by the hazards associated with its administration
  • Actions: Sedative and hypnotic with antiepileptic effects

Piracetam

  • Used as tertiary treatment for patients with generalized myoclonic seizures
  • Actions: Nootropic with CNS protective properties against hypoxia

Prednisolone

  • Used as 1st-line treatment for patients with infantile spasms without tuberous sclerosis

Propofol

  • As an anesthetic, it is used in conjunction with assisted ventilation to control refractory status epilepticus
  • Actions: Short-acting anesthetic

Tetracosactide

  • Also recommended for patients with non-tuberous sclerosis-caused infantile spasms

Thiopental sodium

  • Treatment option for patients with refractory convulsive status epilepticus
  • Actions: Short-acting barbiturate anesthetic

Non-Pharmacological Therapy

Vagus Nerve Stimulation

  • Adjunctive intervention to reduce frequency of seizures in patients with focal to bilateral tonic-clonic or generalized onset seizures refractory to anticonvulsants
  • Optional treatment for patients with contraindications for surgery

Nutrition

  • A ketogenic diet may help in the management of pediatric patients
    • Studies have shown marked reduction in seizure frequency in children on high fat, low carbohydrate controlled protein (ketogenic) diet
  • Modified Atkins diet and low glycemic index treatment may also be considered as an alternative to ketogenic diet

Psychological Interventions

  • Eg relaxation techniques, cognitive behavior therapy
  • May be helpful in pediatric patients with focal epilepsy

Treatment Maintenance

  • Routine level monitoring of anti-epileptic drug is not recommended in patients but may be considered
  • Continue treatment for 2-5 years
  • If patient is seizure-free after 2-5 years, drug withdrawal may be considered based on patient preference, seizure type and history
  • Withdraw treatment gradually, over a few months, to prevent recurrent seizures
  • Patients already receiving anticonvulsant drugs who present with an unexplained seizure should have an anticonvulsant level checked
  • Withdraw 1 drug at a time in combination therapy
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 21 Nov 2020
Antiviral treatment with tenofovir alafenamide fumarate (TAF) during pregnancy in highly viraemic mothers effectively prevents mother-to-child transmission (MTCT) of hepatitis B virus (HBV) with no safety concerns, according to two studies presented during the AASLD 2020 Liver Meeting.